Organogenesis Holdings Inc. reported net revenue of $126.7 million for the fourth quarter of 2024, a 27% increase from $99.7 million in Q4 2023. This growth was driven by a 27% increase in Advanced Wound Care product revenue and a 24% increase in Surgical & Sports Medicine product revenue.
The company achieved a net income of $7.7 million, or $0.05 per share, for the fourth quarter of 2024, a significant improvement from a net loss of $0.6 million in the prior year. For the full year 2024, net revenue reached $482.0 million, an 11% increase over 2023, with Adjusted EBITDA growing 17% to $49.8 million.
As of December 31, 2024, Organogenesis held $136.2 million in cash and cash equivalents with no outstanding debt obligations, reflecting a strengthened balance sheet. The company provided full-year 2025 net revenue guidance of $480 million to $510 million and anticipates submitting the ReNu Biologics License Application (BLA) by the end of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.